Mark E. Schnute
University of Illinois at Urbana–Champaign
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark E. Schnute.
Journal of Pharmacology and Experimental Therapeutics | 2010
James K. Gierse; Atli Thorarensen; Konstantine Beltey; Erica L. Bradshaw-Pierce; Luz A. Cortes-Burgos; Troii Hall; Amy Johnston; Michael P. Murphy; Olga V. Nemirovskiy; Shinji Ogawa; Lyle E. Pegg; Matthew James Pelc; Michael J. Prinsen; Mark E. Schnute; Jay M. Wendling; Steve Wene; Robin A. Weinberg; Authur Wittwer; Ben S. Zweifel; Jaime L. Masferrer
Autotaxin is the enzyme responsible for the production of lysophosphatidic acid (LPA) from lysophosphatidyl choline (LPC), and it is up-regulated in many inflammatory conditions, including but not limited to cancer, arthritis, and multiple sclerosis. LPA signaling causes angiogenesis, mitosis, cell proliferation, and cytokine secretion. Inhibition of autotaxin may have anti-inflammatory properties in a variety of diseases; however, this hypothesis has not been tested pharmacologically because of the lack of potent inhibitors. Here, we report the development of a potent autotaxin inhibitor, PF-8380 [6-(3-(piperazin-1-yl)propanoyl)benzo[d]oxazol-2(3H)-one] with an IC50 of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood. PF-8380 has adequate oral bioavailability and exposures required for in vivo testing of autotaxin inhibition. Autotaxins role in producing LPA in plasma and at the site of inflammation was tested in a rat air pouch model. The specific inhibitor PF-8380, dosed orally at 30 mg/kg, provided >95% reduction in both plasma and air pouch LPA within 3 h, indicating autotaxin is a major source of LPA during inflammation. At 30 mg/kg PF-8380 reduced inflammatory hyperalgesia with the same efficacy as 30 mg/kg naproxen. Inhibition of plasma autotaxin activity correlated with inhibition of autotaxin at the site of inflammation and in ex vivo whole blood. Furthermore, a close pharmacokinetic/pharmacodynamic relationship was observed, which suggests that LPA is rapidly formed and degraded in vivo. PF-8380 can serve as a tool compound for elucidating LPAs role in inflammation.
Pure and Applied Chemistry | 1994
Scott E. Denmark; Mark E. Schnute; Atli Thorarensen; Donald Stuart Middleton; Andreas Stolle
Bbstract; Nitroalkenes have proven to be extremely versatile 4x-components in heterodiene [4+2]-cycloadditions. Our efforts in this area have been intensively methodological with focus on the reaction scope, mechanism, stereoselectivity and transformations of the cycloadducts. The three modes of tandem inter [4+2]/ intra [3+2] cycloaddition, fused, spiro and bridged have been documented. An efficient and highly selective synthesis of (-)-hastanwine has been completed.
Journal of the American Chemical Society | 1994
Scott E. Denmark; Brian D. Griedel; Diane Mary Coe; Mark E. Schnute
Archive | 2001
Gordon L. Bundy; Fred L. Ciske; Michael J. Genin; Steven E. Heasley; Scott D. Larsen; Byung Hyun Lee; Paul D. May; John R. Palmer; Mark E. Schnute; Valerie A. Vaillancourt; Atli Thorarensen; Allison J. Wolf; Nancy Anne Wicnienski; David Wilhite
Journal of Organic Chemistry | 1995
Scott E. Denmark; Mark E. Schnute; Lawrence R. Marcin; Atli Thorarensen
Journal of Organic Chemistry | 1995
Scott E. Denmark; Mark E. Schnute
Journal of Organic Chemistry | 1993
Scott E. Denmark; Mark E. Schnute; C. B. W. Senanayake
Journal of Organic Chemistry | 1991
Scott E. Denmark; Mark E. Schnute
Journal of Organic Chemistry | 1994
Scott E. Denmark; Mark E. Schnute
Archive | 2012
Scott A. Long; Atli Thorarensen; Mark E. Schnute